Heron Therapeutics, Inc. (HRTX) financial statements (2022 and earlier)

Company profile

Business Address 4242 CAMPUS POINT COURT, SUITE 200
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:15820939133217251131
Cash and cash equivalents9110572321451375
Short-term investments67103319 283856
Other undisclosed cash, cash equivalents, and short-term investments0003010(0)0
Receivables35424065422 
Inventory, net of allowances, customer advances and progress billings48422539105 
Inventory48422539105 
Other undisclosed current assets13222311444
Total current assets:25431447944722862135
Noncurrent Assets
Operating lease, right-of-use asset101614
Property, plant and equipment24232015653
Other noncurrent assets18000000
Total noncurrent assets:51393415653
TOTAL ASSETS:30635451346223467138
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities45425563452212
Accounts payable413171973
Accrued liabilities262837331764
Employee-related liabilities15141513985
Debt  2    
Due to related parties    25  
Deferred revenue and credits31 
Other undisclosed current liabilities2660402931167
Total current liabilities:7110397921033920
Noncurrent Liabilities
Long-term debt and lease obligation1571512    
Long-term debt, excluding current maturities149      
Operating lease, liability81512
Liabilities, other than long-term debt     50 
Due to related parties     50 
Other undisclosed noncurrent liabilities(8)(15)     
Total noncurrent liabilities:1571512  50 
Total liabilities:228117109921038920
Stockholders' equity
Stockholders' equity attributable to parent78236404370131(21)118
Common stock1111100
Additional paid in capital1,6901,6281,5681,330914564531
Accumulated other comprehensive income (loss)(0)00(0)(0)(0)(0)
Accumulated deficit(1,613)(1,393)(1,165)(961)(783)(586)(413)
Total stockholders' equity:78236404370131(21)118
TOTAL LIABILITIES AND EQUITY:30635451346223467138

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues868914677311 
Revenue, net311 
Cost of revenue
(Cost of Goods and Services Sold)
(46)(36)(62)(28)(5)(0) 
Gross profit:40528450261 
Operating expenses(258)(281)(295)(261)(225)(172)(97)
Other undisclosed operating income   2850 
Operating loss:(218)(228)(211)(184)(195)(171)(97)
Nonoperating income (expense)(3)165(3)(2)(1)
Investment income, nonoperating04761  
Other nonoperating income (expense)(1)(1)02(0)00
Interest and debt expense(2)(2)(1)(3)(4)(3)(1)
Net loss:(223)(229)(206)(182)(201)(176)(99)
Other undisclosed net income attributable to parent2213431
Net loss available to common stockholders, diluted:(221)(227)(205)(179)(197)(173)(98)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(223)(229)(206)(182)(201)(176)(99)
Comprehensive loss:(223)(229)(206)(182)(201)(176)(99)
Other undisclosed comprehensive income, net of tax, attributable to parent2223431
Comprehensive loss, net of tax, attributable to parent:(221)(227)(205)(179)(197)(173)(98)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: